-

Agilent Acquires Polymer Standards Service, Broadening Offerings for GPC/SEC Polymer Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization. PSS specializes in hardware and software solutions used in defining the makeup and creation of molecular structures. The company provides complete solutions for gel permeation chromatography (GPC) and size exclusion chromatography (SEC) used in applications to determine the molecular weight and size distribution of macromolecules.

The acquisition broadens and extends Agilent’s product portfolio and customer offerings, particularly in the chemical and biopharmaceutical industries for the analysis of natural and synthetic polymers such as nucleic acids, proteins, monoclonal antibodies, polysaccharides, and synthetic plastic.

“We’re extremely pleased to have the PSS team join Agilent to help us expand our leadership in liquid chromatography and the GPC/SEC market,” said Jacob Thaysen, president, Agilent Life Sciences and Applied Markets Group. “The advanced PSS hardware, software, columns and reference materials we’re adding to our portfolio will enhance our offerings and ensure we deliver the broad spectrum of LC equipment, GPC/SEC analytics and software our customers value.”

By acquiring PSS, Agilent will also add a key software component to complement its lineup of GPC/SEC products. In addition, Agilent will be able to use its global presence to expand the use of PSS products and expertise more widely. Agilent customers in the chemical, biopharmaceutical and other key segments will now also be able to take advantage of PSS technology more broadly because of Agilent’s strong global presence in those markets.

“This is a very strategic move for PSS and Agilent,” said Thorsten Hofe, managing director at PSS. “Together we can provide our customers a full range of GPC and LC products and extend the reach of PSS products into new, fast-growing markets. It’s an exciting time for the PSS team.”

Founded in 1985, PSS is privately held and is based in Mainz, Germany, with additional operations in Amherst, Mass. Financial terms of Agilent’s acquisition of PSS were not disclosed.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Media Contact:
Sarah Litton
669-255-7696
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
408-345-8948
parmeet_ahuja@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent Technologies has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization.
Release Versions

Contacts

Media Contact:
Sarah Litton
669-255-7696
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
408-345-8948
parmeet_ahuja@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...

Agilent Announces Cash Dividend of 25.5 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analyti...

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and con...
Back to Newsroom